Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo.
about
Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastomaAngiogenesis promoted by vascular endothelial growth factor: regulation through alpha1beta1 and alpha2beta1 integrinsThe Shc-related adaptor protein, Sck, forms a complex with the vascular-endothelial-growth-factor receptor KDR in transfected cellsVEGF-Trap: a VEGF blocker with potent antitumor effects.Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alphaAcquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expressionIdentification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activityInhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growthA peptide corresponding to the neuropilin-1-binding site on VEGF165 induces apoptosis of neuropilin-1-expressing breast tumour cellsNitric-oxide synthase trafficking inducer is a pleiotropic regulator of endothelial cell function and signaling.Discovering collectively informative descriptors from high-throughput experimentsInhibitory effects of anti-VEGF antibody on the growth and angiogenesis of estrogen-induced pituitary prolactinoma in Fischer 344 Rats: animal model of VEGF-targeted therapy for human endocrine tumors.Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in miceAn anti-vascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis cancer vaccine for the treatment of primary and metastatic Her-2/neu+ breast tumors in a mouse model.Angiogenesis in cancer: the role of endothelin-1.In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors.Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in miceInhibitory effect of Bifidobacterium infantis-mediated sKDR prokaryotic expression system on angiogenesis and growth of Lewis lung cancer in mice.The carboxyl terminus controls ligand-dependent activation of VEGFR-2 and its signalingNeutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapyInhibition of tumor growth and angiogenesis by soluble EphB4.Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors.Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooptionRole of vascular permeability factor/vascular endothelial growth factor in eye disease.Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinomaTargeting angiogenesis in esophagogastric adenocarcinoma.Early induction of angiogenetic signals in gliomas of GFAP-v-src transgenic mice.Expression of vascular endothelial growth factor induces an invasive phenotype in human squamous cell carcinomas.IL-11 up-regulates Tie-2 expression during the healing of gastric ulcers in rats.Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate.A decrease in maternal plasma concentrations of sVEGFR-2 precedes the clinical diagnosis of preeclampsiaAntiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis.Reduction of tumorigenicity of SMMC-7721 hepatoma cells by vascular endothelial growth factor antisense gene therapy.Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal.Distinct angiogenic mediators are required for basic fibroblast growth factor- and vascular endothelial growth factor-induced angiogenesis: the role of cytoplasmic tyrosine kinase c-Abl in tumor angiogenesis.Loss of ovarian function promotes angiogenesis in human ovarian carcinomaPrognostic value of angiopoietin-2 for death risk stratification in patients with metastatic colorectal carcinoma.Clinical Trials of Antiangiogenesis Therapy in Recurrent/Persistent and Metastatic Cervical Cancer.Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours.
P2860
Q24295370-5C37C341-D35E-4298-8568-581A3B8DCB2BQ24311459-7BAD408C-BE03-40F8-89DF-26C0027BD597Q24532025-DC403F3A-E86D-4437-9D48-EE6F959A4026Q24535043-ED4B01DB-6718-4A85-B265-A2CCF3F773B1Q24610199-DBB4788B-CDDC-4FD5-BA46-C189CE457556Q24623398-37836C8F-B4AE-4246-9D53-D5F8679708A1Q24677555-00423F8E-DB7A-41A1-89DD-9AEE6956A383Q28578750-4D3DC6DC-901E-4D9E-9169-61AC2D3925DDQ29543360-8E22228B-4537-4835-B185-9D533585D967Q30008769-032125B4-F013-4E97-8E92-7AF72E54E2F5Q33519717-239F93DF-4BEE-4678-A3BB-4D3CB9AB74D9Q33591382-39326E38-7DF0-4456-98DF-BAAE67158D2CQ33713224-08FE5F37-5482-4068-9F0C-87FCD9BE5435Q33773435-431FF23A-B657-4A95-B416-DEE0F216A83EQ33822741-D5EF0B0F-50FD-463B-8A07-2F9CCC7CDC12Q34030193-810536D3-24A1-4E61-B036-AE641C8F4981Q34245416-B04034B9-6DF1-484C-BB31-FE4FB3C4FEF5Q34247933-913B9D48-3ED2-4829-91E9-DE13C1642ACBQ34623704-C6C6ECB3-E198-4D63-B975-B193B782A788Q34743875-C2203914-B2EF-480B-8C3A-00F2145C27DCQ34770033-796027B0-1FE6-42D9-9CDC-63310E4E1609Q34852517-47E3BB21-EB93-4FBA-BFA1-1C2CCABA7CE4Q34997337-EE750127-F5C3-4428-BCD5-697E881E952BQ35300661-C1F90B3D-111C-47E4-B77C-E0618B1ED1C3Q35362327-57E8129A-64DE-4601-8228-FE34E3FFB852Q35584958-E0C4BEDE-7D4F-49E9-8FE2-5F3A59D09BCCQ35745271-7B12052D-E6B5-4985-8D56-D140C2E79203Q35793483-6C8B7F5B-3032-4F60-80BD-EBEBCC554364Q36178709-FD1F4D69-13A0-4F13-BEA8-1F630B3C5F27Q36220799-8AA479AB-3446-4605-99AD-5810FAD8CF91Q36221448-619C2229-AA82-45D4-A506-55B8EE17C94DQ36223383-1792AA65-D4E8-4BDE-AADE-EB9C4CBC8E5BQ36295017-1B483F65-16DE-459A-A2C0-D7AC69779B07Q36397313-C9940B7C-2877-4EC4-A216-1203B28E944DQ36558878-525CBCA9-2B35-4583-B248-94D91E883C62Q36631240-F581DB19-D6EB-4B31-A4AA-A1E815793D1DQ36722080-FAFD59B6-92EB-48A2-9C35-C1F589A72F66Q36724011-0F274A9B-78A1-4363-B86D-0D3BAD308826Q36884393-05CD2D57-EF45-4AAA-B167-171C270548E5Q36977529-3E80F01F-0C6C-4C1F-9C12-66D9F61B4836
P2860
Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo.
@en
Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo.
@nl
type
label
Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo.
@en
Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo.
@nl
prefLabel
Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo.
@en
Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo.
@nl
P2093
P1433
P1476
Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo.
@en
P2093
Millauer B
Shawver LK
P304
P407
P577
1996-04-01T00:00:00Z